Cosomil Inc. today announced the completion of its Series A1 financing round, led by Delight Ventures, with participation from new investors Animal Spirits and Gogin Capital, as well as existing investors ANRI and Green Core.

Through this financing, Cosomil will further accelerate research, development, and real-world deployment of its blood-based cancer screening tests powered by its proprietary single-molecule enzyme activity-based liquid biopsy technology, in both Japan and the United States.

Background of the Financing

Cosomil is an academia-originated startup developing novel diagnostic technologies based on its proprietary single-molecule enzyme activity-based liquid biopsy platform, which enables ultra-high-sensitivity analysis of enzyme activity in blood at the single-molecule level (Science Advances, 2020, 6, eaay0888). Leveraging this platform, Cosomil is advancing the development of a blood-based screening test aimed at the early detection of pancreatic cancer.

Since its previous financing, the Company has made significant progress in both development and commercialization. Through biomarker discovery studies and clinical research using blood samples collected in Japan and the United States, Cosomil has confirmed that the test outperforms existing biomarkers that supports clinical adoption for pancreatic cancer screening in Japan.

Based on these results, clinical testing services began in July 2025 through BML, Inc., one of Japan’s leading clinical laboratory companies. The test is currently being used in a large-scale prospective clinical study involving approximately 10,000 participants, aimed at prospectively evaluating its performance.

In preparation for regulatory submission, Cosomil has obtained the In Vitro Diagnostic Manufacturer and Marketing Authorization (MAH) license in Japan, which qualifies the Company to submit and commercialize IVD products, subject to product approval.

In parallel, the Company has presented its research findings at major academic conferences in the United States and has engaged in consultations with the U.S. Food and Drug Administration (FDA), advancing development with a view toward expansion beyond Japan and into the U.S. market.

The newly raised capital will be used to support clinical development and regulatory preparation for PMDA approval of the pancreatic cancer biomarker, as well as to build research, clinical development, and business development capabilities for the U.S. market.

Cosomil will continue advancing toward the social implementation of diagnostic technologies that enable early cancer detection, while preparing for its next phase of growth. The Company also plans to consider additional fundraising aligned with future business milestones.

Comment from Yu Kagami, CEO of Cosomil

“We are delighted to have completed our Series A1 financing. What began as research-driven innovation has now entered a true phase of social implementation, including prospective clinical studies and regulatory preparation. Empowered by this investment and the collective efforts of our team, we will continue advancing toward regulatory approval and global expansion of our diagnostic tests.”

About Cosomil Inc.

Cosomil Inc. is a startup company developing novel diagnostic technologies based on its proprietary single-molecule enzyme activity-based liquid biopsy platform, which enables ultra-high-sensitivity analysis of enzyme activity in blood at the single-molecule level.

The technology combines fluorescence-based enzyme activity detection developed by Associate Professor Toru Komatsu of The University of Tokyo with single-molecule analysis technology developed by Chief Scientist Rikiya Watanabe of RIKEN.

The Company was founded in April 2022 with support from the Japan Science and Technology Agency (JST) START Program. Since April 2024, Cosomil has been selected for the NEDO Deep-Tech Startup Support Program (DTSU), STS Phase in Japan.